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Abstract
Background: Studies of neuromyelitis optica (NMO), an autoimmune disease of the central nervous system (CNS),
have demonstrated that autoantibodies against the water channel aquaporin-4 (AQP4) induce astrocyte damage
through complement-dependent cytotoxicity (CDC). In developing experimental models of NMO using cells,
tissues or animals from mice, co-administration of AQP4-IgG and normal human serum, which serves as the
source of human complement (HC), is required. The sensitivity of mouse CNS cells to HC and CDC in these
models is not known.
Methods: We used HC and recombinant monoclonal antibodies (rAbs) against AQP4 to investigate CDC on
mouse neurons, astrocytes, differentiated oligodendrocytes (OLs), and oligodendrocyte progenitors (OPCs) in
the context of purified monocultures, neuroglial mixed cultures, and organotypic cerebellar slices.
Results: We found that murine neurons, OLs, and OPCs were sensitive to HC in monocultures. In mixed murine
neuroglial cultures, HC-mediated toxicity to neurons and OLs was reduced; however, astrocyte damage induced by
an AQP-specific rAb #53 and HC increased neuronal and oligodendroglial loss. OPCs were resistant to HC toxicity in
neuroglial mixed cultures. In mouse cerebellar slices, damage to neurons and OLs following rAb #53-mediated CDC
was further reduced, but in contrast to neuroglial mixed cultures, astrocyte damage sensitized OPCs to complement
damage. Finally, we established that some injury to neurons, OLs, and OPCs in cell and slice cultures resulted from the
activation of HC by anti-tissue antibodies to mouse cells.
Conclusions: Murine neurons and oligodendroglia demonstrate variable sensitivity to activated complement
based on their differentiation and culture conditions. In organotypic cultures, the protection of neurons, OLs,
and OPCs against CDC is eliminated by targeted astrocyte destruction. The activation of human complement
proteins on mouse CNS cells necessitates caution when interpreting the results of mouse experimental
models of NMO using HC.
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Background
Neuromyelitis optica (NMO) is a severe autoimmune
disease of the central nervous system (CNS) associated
with predilection for the spinal cord and optic nerve.
Histopathology and animal models demonstrate that
complement-dependent cytotoxicity (CDC) plays a key
role in the initiation of the NMO pathology [1].
The complement system consists of over 30 compo-
nents that are normally found inactive in serum and is an
essential immune regulator of host defense to infection,
cell integrity, and tissue homeostasis. The complement
cascade can be activated by antigen-antibody complexes
(classic pathway) or the antibody-independent lectin (lec-
tin pathway). Additionally, the alternative pathway serves
to amplify the classic and lectin pathways. All three path-
ways converge to trigger activation of terminal comple-
ment components resulting in cell lysis [2]. In the CNS,
the complement cascade regulates synaptic refinement
and neuronal survival during development [3, 4] and plays
a role in maintaining brain homeostasis in adulthood [5].
There is mounting evidence that complement synthesis
and activation are increased in neurodegenerative and
neuroinflammatory environments [6].
NMO lesions show perivascular deposition of im-
munoglobulin and activated complement [7, 8], and acti-
vated complement proteins are elevated in the serum
and cerebrospinal fluid (CSF) of NMO patients [9, 10].
Serum autoantibodies (NMO-IgG) against the water
channel aquaporin-4 (AQP4) are found in most NMO
patients [11]. In the CSF of NMO-IgG positive patients,
there exists a dynamic and enriched population of ex-
panded plasmablast clones producing AQP4-specific
antibodies [12]. Both serum NMO-IgG and CSF-derived
AQP4-specific monoclonal recombinant antibodies re-
capitulate NMO pathology when microinjected into the
CNS, added to ex vivo spinal cord slices in the presence
of human complement proteins [13], introduced into ro-
dent models of CNS inflammation [12, 14], or injected
into mice pretreated with Freund’s complete adjuvant
[15]. Astrocytes are selectively targeted in NMO, as
evidenced by the extensive loss of immunoreactivity for
the astrocytic proteins AQP4 and glial fibrillary acidic
protein (GFAP) [7]. Moreover, inhibition of the classic
complement pathway blocks neuropathology in both in
vitro and in vivo models of NMO [16].
In developing experimental mouse models of NMO in
vivo, ex vivo, or in vitro, co-administration of AQP4-IgG
and normal human serum as the source of human com-
plement (HC) is required to produce NMO pathological
lesions [17]. The weak activity of intrinsic mouse com-
plement [18] and the presence of complement inhibi-
tor(s) in the mouse serum [19] may combine to prevent
rigorous complement activation in the absence of added
HC in NMO models. Additional effects of HC on other
CNS cells have not been characterized in NMO animal
models.
In this study, we investigated the toxic effects of HC on
murine neurons, astrocytes, differentiated oligodendro-
cytes (OLs), and oligodendrocyte progenitors (OPCs) in
the presence or absence of AQP4-IgG in several in vitro
and ex vivo CNS culture systems (monocultures, neuro-
glial mixed cultures, and organotypic cerebellar slice cul-
tures). Our results reveal that neurons, OLs, and OPCs
derived from mice display differential sensitivity to HC de-
pending on the complexity of the neuroglial environment,
and that AQP4-IgG-targeted astrocyte destruction results
in secondary oligodendrocyte and neuronal loss.
Methods
Recombinant antibodies
The recombinant monoclonal human anti-AQP4 anti-
body #53 (rAb #53) was constructed from a clonally ex-
panded plasmablast recovered from the cerebrospinal
fluid (CSF) of a seropositive NMO patient. The control
human antibody was generated from a CSF plasmablast
sorted from a chronic meningitis patient. Recombinant
antibodies were produced using a dual vector transient
transfection system and purified with protein A-
sepharose (Sigma-Aldrich, St. Louis, MO) as previously
described [12].
Biochemical assays and reagents
Lactate dehydrogenase (LDH) cytotoxicity assays were
performed on cell culture supernatants using the LDH
cytotoxicity detection kit (TakaRa Bio, Shiga, Japan). Except
for IncuCyte live imaging (see below), propidium iodide
(PI) (Sigma) was used at 5 μg/ml in the culture medium to
label dead cells in cell and organotypic slice cultures. Nor-
mal, C1q-depleted, C3-depleted, C4-depleted, C5-depleted,
and C9-depleted human serum (Complement Technology,
Tyler, TX) were used as the source of human complement.
Pooled and individual normal human (Sigma and Innova-
tive Research), rat (Complement Technology), and mouse
(Complement Technology and Innovative Research) sera
were used as sources of complement for comparative com-
plement experiments. Serum proteins were obtained by
passing the serum through Amicon Ultra 3KD centrifugal
filters (Millipore, Billerica, MA). Protein A/G plus agarose
(Thermo Fisher Scientific, Waltham, MA) was incubated
with human serum overnight at 4 °C, then centrifuged and
discarded to deplete IgGs in the serum. Heat-inactivated
serum was obtained by incubating normal serum at 58 °C
for 30 min.
Primary cell cultures
Primary astrocyte, differentiated oligodendrocyte (OL),
oligodendrocyte progenitor (OPC), and neuronal mono-
cultures, and neuroglia mixed cultures were prepared as
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described from mice (CD-1 or PLP-eGFP [20]) or rats
(Sprague Dawley) (Harlan, Indianapolis, IN) with some
modifications [21–24]. Mixed glial cultures were pre-
pared from P0-1 dissociated cortices and plated in poly-
D-lysine-coated 24-well plates at a density of one brain
per plate. Plates were used for experiments when astro-
cyte layer was confluent and oligodendrocyte cell bodies
were apparent (day 5–8 in culture). Purified oligo-
dendrocyte monocultures were prepared by shaking
flasks of mixed glial cultures overnight at 200 rpm to de-
tach the OPCs. OPCs were plated on poly-D-lysine/lam-
inin coated dishes and maintained in media containing
10 ng/ml PDGF (platelet-derived growth factor)/FGF
(fibroblast growth factor) (Peprotech, Rocky Hill, NJ) for
48–72 h prior to experiments. To differentiate OPCs
into OLs, PDFG/FGF was withdrawn after 48 h and
media supplemented with 40 ng/ml T3 (Sigma). OLs
were used for experiments 24–72 h after exposure to
T3. For neuroglial mixed cultures, P0-1 cortices were
dissected, dissociated in 0.25% trypsin, and cells were
plated on poly-D-lysine/Laminin coated coverslips (BD
Biosciences, Franklin Lakes, NJ) in Neurobasal medium
containing B27 supplement, 0.05 mM L-glutamine,
penicillin-streptomycin (all from Life Technologies) and
5% heat-inactivated FBS (Sigma). Neuronal monocul-
tures were prepared from E15-17 mouse cortex and
cultured in Neurobasal medium in the presence of B27
supplement, 0.05 mM L-glutamine and penicillin-
streptomycin. On day 2–5 in culture, 2 μM ara-C
(Sigma) was added to inhibit the growth of glial cells.
Human cortical neuron cultures (iCell Neurons) were
cultured in iCell proprietary maintenance medium pur-
chased from Cellular Dynamics (Madison, WI). Cell
cultures were maintained at 37 °C in 5 or 8.5% CO2
atmospheric conditions.
Cerebellar slice culture
Sagittal slices (300 μm) were prepared from the cerebella
of C57Bl6 or PLP-eGFP mice at P10 and cultured on
MilliCell 0.4 μm membrane inserts (Millipore) for 10–14
days in media containing 25% inactivated horse serum
[25]. Prior to treatment, slices were switched to a
serum-free Neurobasal medium supplemented with B27,
2 mM GlutaMAX, and 28 mM D-glucose (Sigma).
Immunostaining
Differential labeling of cell surface and internalized proteins
in cell culture
Cell cultures were washed with fresh culture medium,
then incubated with 20 μg/ml recombinant antibody at 4
or 37 °C for 1 h. Cells were then washed and fixed in 4%
paraformaldehyde (Thermo Scientific) in phosphate-
buffered saline (PBS) and rinsed and blocked with 3%
normal goat serum (NGS) and 2% bovine serum albumin
(BSA) in PBS without Triton X-100 (all from Sigma).
Cells were then probed with Alexa-fluor 488 goat anti-
human IgG secondary antibodies (1:500). Subsequently,
cells were blocked overnight with unlabeled goat anti-
human IgG at 0.25 mg/ml at room temperature and
then washed, postfixed, and permeabilized with blocking
buffer containing 0.1% Triton X-100. Alexa-fluor 594
goat anti-human IgG (1:500) was used to probe for intra-
cellular recombinant antibody. After extensive washing,
slides were mounted with ProLong Gold anti-fade reagent
with DAPI (Life Technologies).
Immunostaining of fixed cells and brain sclices
Cell cultures or brain slices were fixed in 4% paraformal-
dehyde in PBS, rinsed, permeabilized in 0.1% (for cells)
or 3% (for slices) Triton X-100 in PBS, and then blocked
with 5% normal goat serum (NGS) or normal donkey
serum (NDS) in PBS containing 0.1% (for cells) or 0.3%
(for slices) Triton X-100 for 1 h. Samples were then in-
cubated with primary antibodies in blocking buffer,
washed, and then probed with secondary antibodies
(Alexa Fluor secondary antibodies, all from Life Tech-
nologies). After washing, the coverslips were mounted
with ProLong Gold anti-fade reagent (Life Technolo-
gies). The brain slices were mounted with Fluoromount-
G (Southern Biotech, Birmingham, AL), placed under
the glass covers, and sealed. Primary antibodies used in
the immunostaining were mouse anti-NeuN (Millipore),
mouse anti-β-tubulin (Sigma), rabbit anti-GFAP (DAKO,
Carpinteria, CA), mouse anti-Olig1(Millipore), mouse
anti-O4 IgM (R&D Systems, Minneapolis, MN ), rabbit
anti-LAMP1(Abcam, Cambridge, UK), rabbit anti-
Calbindin (Millipore), mouse anti-C3d (a gift from Dr.
Joshua Thurman, University of Colorado), rabbit anti-
MAC complex (Abcam), and rabbit anti-NG2 and rabbit
anti-Olig2 (both are gifts from Dr. Charles Stiles,
Harvard University).
Microscopy
Fluorescence images were acquired by Zeiss fluorescence
microscope with Axiovision software (Zeiss, Jena,
Germany). Confocal images were acquired by Leica SP5
laser scanning microscope (Leica Microsystems GmbH,
Wetzlar, Germany) and Zeiss LSM 780 microscope or
Olympus FV-1000 confocal microscope (Olympus, Center
Valley, PA).
IncuCyte live cell imaging
Live cell imaging was performed using IncuCyte Zoom
from Essen BioScience (Ann Arbor, MI). Cells were
grown and scanned on 24-well plates in the cell culture
incubator. Each well was scanned with a 10× objective
lens in nine randomly selected positions at 15 min intervals
with high definition phase contrast and epifluorescence
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microscopy using the following filter sets: 460/524 nm
(green fluorescence, to detect enhanced green fluorescent
protein, eGFP) and 585/635 nm (red fluorescence, to de-
tect the DRAQ7 dead cell nuclei; Cell Signaling Technol-
ogy, Danvers, MA). Image processing and cell counting
were performed using IncuCyte software. Oligodendrocyte
lineage cells in the neuroglial mixed cultures were labeled
with eGFP in PLP-eGFP mice [20]. In cell culture, OLs and
OPCs were defined by their distinct morphologies. In the
neuroglia mixed cultures, the majority of oligodendrocytes
were bipolar and tripolar OPCs, while a minority of the
cells displayed a highly complex network of processes and
O4 antigen consistent with differentiating OLs [26]. Neu-
rons and astrocytes were identified by their distinct morph-
ologies. DRAQ7+ cells were classified as dead neurons or
astrocytes based on the different signal intensity and area.
Dead oligodendrocytes were identified as DRAQ7+ cells
with reduced eGFP signal. The identification of different
cell types in mixed cultures was confirmed by immuno-
staining with NeuN (neurons), AQP4 and GFAP (astro-
cytes), Olig1 (a general oligodendrocyte lineage marker),
and O4 (differentiating OLs) (Additional file 1: Figure S1).
To assess the total number of the cells in the cultures,
cells were stained with Cell Trace Calcein red-orange
(Life Technologies) and then scanned and counted
using IncuCyte software.
Quantification and statistical analysis
Cell counts in IncuCyte images were quantified by Incu-
Cyte software. In each well of the 24-well plate, signals
were measured in nine scanned positions and sum-
mated. PLP-eGFP positive cell bodies in the brain slices
were imaged using a Zeiss fluorescence microscope with
20× objective. Images were quantified with ImageJ (Na-
tional Institutes of Health open source). For each slice, 2–
3 images were taken, quantified, and averaged. Slices from
three independent experiments were analyzed. Statistical
analyses were performed by unpaired Student’s t test for
single comparisons or by two-way ANOVA for grouped
comparisons using GraphPad Prism software. Data are
expressed as means ± SD of independent experiments
(n ≥ 3). Significance is reported for p < 0.05.
Results
Human serum as the source of human complement is
cytotoxic to mouse neurons and oligodendrocytes, but
not astrocytes in monocultures
To investigate the effect of HC on murine CNS cells, we
assessed the sensitivity of mouse neurons, oligodendro-
cytes (OLs), oligodendrocyte progenitor cells (OPCs),
and astrocytes to human serum in monocultures. Mono-
cultures were exposed to either PBS as a control or 2–
5% (vol/vol) HC. Cell death was measured by the
addition of DRAQ7 to the media to label dead/dying
cells, followed by IncuCyte live cell imaging. After 4 h of
incubation with 2% HC, 90.0 ± 1.9% of the mouse neur-
onal population was DRAQ7+ (Fig. 1a–b). OLs and
OPCs were also sensitive to HC exposure with 70.8 ±
2.8% and 42.2 ± 5.6% cell death, respectively, after 4 h
incubation (Fig. 1c–f and Additional file 2: Movie 1
and Additional file 3: Movie 2). In contrast, HC did
Fig. 1 Human complement (HC) is toxic to mouse neurons and
oligodendrocytes in monocultures. IncuCyte live imaging of neurons,
mature oligodendrocyte (OL), and oligodendrocyte progenitors (OPC)
monocultures treated with HC (2% in neurons and 5% in OLs and OPCs)
for 4 h. DRAQ7 was added in the culture medium to label dead
cells. a, c, and e Phase contrast images show DRAQ7 staining (red) in
the absence (CTRL) and presence (HC) of human complement. b, d,
and f The percentage of DRAQ7+ neurons (b), OLs (d), and OPCs (f)
increased rapidly following exposure to HC. g and h Astrocytes (AST)
exposed to 5% HC for 4 h showed no evidence of cytotoxicity as
measured and quantified by IncuCyte. CTRL: PBS. Scale bars 100 μm
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not induce astrocyte cell death as determined by
LDH release assay (Fig. 1g) or IncuCyte live cell im-
aging (data not shown). The degree of cell death in
these murine CNS monocultures in the presence of
HC is summarized in Table 1.
Reduced sensitivity of mouse neurons and OLs to HC in
neuroglial mixed cultures
In the CNS, the interaction of neurons and glia may
alter their responses to environmental stressors. We in-
vestigated how mouse neurons and glial cells responded
to HC in mixed cell cultures prepared from PLP-eGFP
[20] mouse pups in which both OPCs and differentiated
OLs were labeled with eGFP. Cell type specific marker
staining showed that the neuroglial mixed cultures con-
sisted of 70% astrocytes (GFAP and AQP4), 10–15%
oligodendroglial cells (Olig1), and 10–15% neurons
(βIII-Tubulin). Most oligodendroglial cells were OPCs,
but occasionally maturing OLs (O4+) were noted
(Additional file 1: Figure S1).
Cell death in mixed cultures was monitored by Incu-
Cyte live imaging. In the mixed cultures, HC was not
toxic to astrocytes (Fig. 2a, arrow heads). Neurons
remained sensitive to HC in the mixed cultures (Fig. 2a,
arrows); however, the magnitude of loss was significantly
reduced. The addition of 5% HC caused 31.4 ± 4.0%
neuronal death in the mixed culture after 4 h incubation
(Fig. 2b and Additional file 4: Movie 3); whereas, HC
resulted in greater than 90% neuronal death in the
monoculture (Fig. 1b). Neuronal death was confirmed by
co-labeling with the dead cell dye propidium iodide (PI)
and neuronal marker NeuN (Fig. 2c).
In the neuroglial mixed cultures, the majority of
eGFP+ oligodendrocyte lineage cells were bipolar and
tripolar progenitors, while a minority of the cells
displayed a highly complex network of processes con-
sistent with differentiated OLs [26]. OLs died rapidly
in the presence of HC alone with 56.0 ± 1.4% of OLs
lost by 4 h (Fig. 2d). OL cell death was reduced, how-
ever, in mixed cultures when compared to monocul-
tures (70.8 ± 2.8%, Fig. 1e). In contrast to their
behavior in monoculture (Fig. 1d–e), OPCs were not
sensitive to HC in the neuroglial mixed cultures, even
after an extended incubation time of 3 days (Fig. 2e and
Additional file 4: Movie 3). As observed in the monocul-
ture, astrocytes remained insensitive to HC in the neuro-
glial mixed culture (Fig. 2a and Additional file 4: Movie 3).
The percent of CNS cell death in mixed cultures is sum-
marized in Table 1.
Targeted astrocyte damage increases HC-mediated
neuron and OL death in mixed cultures
We hypothesized that astrocytes in mixed cultures pro-
vided protection against HC to adjacent oligodendro-
cytes and neurons. To test this, we used a recombinant
monoclonal antibody specific for AQP4 (rAb #53) [12]
to target astrocytes via complement-mediated lysis
(CDC) [13]. Live staining of rAb #53 of astrocytes at 4
or 37 °C displayed a robust membrane staining and dim
cytoplasmic staining, indicating only a small portion of
AQP4 being internalized from the cell surface (Fig. 3a).
In combination with HC, rAb #53 induced significant
astrocyte death, resulting in a marked increase of LDH
in the culture medium (Fig. 3b).
We monitored the kinetics of neuron, oligodendrocyte,
and astrocyte death in the mixed cultures following tar-
geted rAb #53-mediated astrocyte damage with IncuCyte
live cell imaging. No cell death was noted with rAb #53
or isotype control (Iso) without the presence of HC.
Treatment with rAb #53+ 5% HC induced rapid cell
death, notably among astrocytes (Fig. 4a–b). Dead neu-
rons were identified as small round DRAQ7+ particles
with high fluorescence intensity (Fig. 4a, arrows),
whereas dead astrocytes were distinguished as larger but
less intense DRAQ7+ cells (Fig. 4a, arrow head). Dead
astrocytes floated into the culture supernatant, resulting
in areas of astrocyte depletion (Fig. 4a, circled area).
After the peak of astrocyte death (4 h), viable astrocytes
repopulated these areas (Additional file 5: Movie 4).
Neuronal death increased in the presence of rAb #53-
mediated astrocyte destruction, with approximately 70%
of neurons dying within 2 h. While some neuronal death
may result from their sensitivity to HC alone, only 30%
neuronal death was observed with Iso+HC (Fig. 4c) or
HC alone (Fig. 2b–c). Astrocyte loss induced by rAb #53
plus HC also increased the death of OLs (Fig. 4d). In
contrast, rAb #53-mediated astrocyte destruction caused
no loss of OPCs (Fig. 4e). The percent cell death is
summarized in Table 1.
Table 1 Summary of cell death in monoculture, neuroglial
mixed culture and brain slices
Cell death Monoculturea Mixed
cultureb
Brain slicesc
Mouse AST HC No death No death No death
#53+HC 33.9 ± 1.5% 32.0 ± 1.7% Damage from 8 h
Mouse N HC 93.4 ± 4.0% 31.4 ± 4.0% 17.4 ± 0.7%
#53+HC 97.7 ± 2.1% 72.3 ± 11.1% 52.3 ± 2.7%
Mouse OL HC 70.8 ± 2.8% 56.0 ± 1.4% 26.4 ± 5.7%
#53+HC 61.3 ± 7.8% 73.2 ± 5.4% 43.7 ± 3.9%
Mouse OPC HC 42.2 ± 5.6% No death No death
#53+HC 36.9 ± 5.6% No death 46.9 ± 16.9%
Abbreviations: AST astrocyte, N neuron, OL mature oligodendrocyte, OPC
oligodendrocyte precursor cell, HC human complement, #53+HC rAb #53 plus
human complement.
aPercentage of cell death at 4 h
bPercentage death at 4 h except neuron (N) death with #53+HC which was
maximal at 1.5 h
cCell death in brain slices at 48 h
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The sensitivity of neurons, OL, and astrocytes to HC
was not dependent on the source of human sera. Both
pooled and single donor samples of HC from different
vendors were tested for cytotoxic activity on mixed neu-
roglial cultures and produced identical cytotoxic effects
(Additional file 1: Figure S2 and Table S1). Consistent
with previous reports [18, 19], we did not detect any
cytotoxic effects of mouse serum on neurons or OLs in
mixed culture in the presence or absence of AQP4-specific
rAb #53 (Additional file 1: Figure S2 and Table S1).
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Fig. 2 Mixed cultures of neurons, oligodendrocytes, and astrocytes demonstrate reduced complement cytotoxicity. Neuroglial mixed cultures
prepared from PLP-eGFP mouse pups were treated with 5% HC for 4 h in the presence of DRAQ7 and imaged using IncuCyte. a Phase contrast
images of IncuCyte cultures treated with human complement (HC) at 0 and 4 h. Insert: Fluorescence image showing oligodendrocytes (PLP-eGFP;
green) and dead cells (DRAQ7; red). Arrows: neurons. Arrow heads: astrocytes. b Quantitation of the percentage of DRAQ7+ neurons at 2 and 4 h
in the presence of 2% or 5% HC. c Fluorescence image and quantitation of the percentage of PI+ dead neurons following exposure to 5% HC for
4 h. Left: fluorescence image of mixed cultures exposed to CTRL or HC and stained with PI (red) followed by NeuN (green) at 4 h. Note the dead
neurons (PI+/NeuN+) in the HC-treated cultures. d, e IncuCyte fluorescence images (left) and quantitation of (d) differentiated oligodendrocyte
(OL, arrows) and (e) oligodendrocyte progenitor (OPC) death in mixed cultures. OPCs and differentiated OLs were defined by morphology. More
than 150 differentiated oligodendrocytes (OL) were counted for each experiment. CTRL: PBS. Scale bars 100 μm
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Sensitivity to HC is further modified and attenuated in
mouse organotypic cerebellar slices
In order to determine the sensitivity of CNS cells to HC
in a complex tissue network, cell death was examined in
mouse organotypic cerebellar slices. Slices treated with
HC alone had no effect on astrocyte morphology and
tissue structure (Fig. 5a). A low level of neuronal death
was detected at 48 h following HC treatment: 17.4 ±
0.7% of calbindin-positive neurons were PI-positive
(Fig. 5b–c). Neuronal death, however, was not limited to
Purkinje cells, as coincident NeuN and PI staining showed
a general loss of neurons throughout the slice, including
the granule cell layer (Additional file 1: Figure S3).
In cerebellar slice cultures, all PLP-eGFP positive cells
differentiated into mature oligodendrocytes and co-
localized with CC1 (data not shown), a mature oligo-
dendrocyte marker [27]; OPCs no longer expressed
eGFP [20]. HC caused a significant loss of PLP-eGFP+
cell bodies from 24 h treatment. At 48 h, the number of
eGFP+ oligodendrocyte cell bodies was reduced by 25%
with some PLP-eGFP+ OLs displaying disorganized
processes (Fig. 5d–e). OPCs were visualized with NG2
and Olig2 co-staining and did not express PLP-eGFP
(Fig. 5f, arrows). No loss of OPCs was observed in cere-
bellar slices treated with HC alone for 48 h (Fig. 5f–g).
To further investigate the role of astrocyte injury on
cell-specific survival within organotypic cultures, we
treated cerebellar slices with NMO rAb #53+HC. In rAb
#53+HC-treated slices, astrocytes became swollen, and
the network of astrocytic processes was disrupted within
8 h. At 48 h, massive destruction of the astrocyte net-
work was apparent (Fig. 6c–d). In contrast, no signifi-
cant morphological changes in astrocytes were detected
using an isotype control rAb+HC or rAb #53 alone
(Fig. 6a–b). At 48 h, neuronal death in the slices treated
with rAb #53+HC increased about threefold compared
to HC alone: 52.3 ± 2.7% calbindin-positive neurons were
PI-positive following rAb #53+HC (Fig. 7a–b), as com-
pared with 17.4 ± 0.7% with HC alone (Fig. 5b–c). With
increasing astrocyte destruction, the loss of OLs rapidly
escalated: approximately 30% of OLs were lost at 12 h,
whereas, at 48 h, about 50% of OLs were lost (Fig. 7c–d).
The loss of OLs at 48 h was increased approximately 1.6-
fold compared to HC alone (Fig. 5d–e). Surprisingly, ap-
proximately 50% of NG2+ Olig2+ OPCs were lost in slices
by 24 h after treatment with rAb #53+HC (Fig. 7e–f, ar-
rows), despite their lack of sensitivity to HC in neuroglial
mixed cultures following astrocyte loss (Fig. 4e and
Additional file 5: Movie 4) and their resistance to HC
alone in organotypic cultures. The results are summarized
in Table 1.
Sensitivity of murine cells to HC is due to cross-reactive
IgGs and requires complement activation
Because of the intrinsically weak activity of mouse com-
plement [18] and the presence of complement inhibi-
tor(s) in the mouse serum [19], complement sourced
from human serum is required to trigger complement
activation in NMO models. Our results demonstrate that
murine neurons and oligodendroglia are sensitive to HC
in monocultures and mixed cell cultures. Human neu-
rons, however, did not demonstrate a similar sensitivity
to HC (Additional file 1: Figure S4). Similarly, rat OPCs
and OLs showed no sensitivity to rat serum (Additional
file 1: Figure S4). These data suggest that human serum
may contain cross-reactive antibodies that are mediating
murine neuron and oligodendrocyte cell death. Using
heat inactivation, which eliminated complement protein
activity but maintained human antibody function, we ob-
served binding of HC-derived human IgG to murine
neurons, OLs, OPCs, and astrocytes (Additional file 1:
Figure S5). Furthermore, IgG-depleted HC was not toxic
to mouse neurons, OPCs or OLs in the monocultures or
in mixed cell culture, and retained its ability to induce






















Fig. 3 AQP4-specific NMO rAb #53 causes rapid damage to mouse
astrocytes in the presence of HC. a Differential immunofluorescent
labeling of rAb #53 on cell surface and intracellular compartments in
live astrocyte cultures at 4 °C or 37 °C. b LDH activity was measured
in the clarified cell-free culture supernatant recovered from the astrocyte
monoculture treated with rAbs #53 with or without 5% HC for 4 h
at 37 °C. Iso: negative isotope control rAb. Scale bars 20 μm
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(Fig. 8a–b and e–f ). To determine if the complement
pathway is required for HC-mediated cell death of mur-
ine cells, we heat inactivated or depleted HC of com-
plement components (C1q, C3, C5, or C9) and applied
it to murine monocultures. Inactivation of the comple-
ment pathway prevented HC-mediated cell death of
murine cells (Fig. 8c–f ). Taken together, these results
suggest cross-reactive antibodies in human sera bind
to the surface of mouse cells and may activate the
complement cascade.
Complete activation of the complement cascade leads
to the formation of the terminal membrane attack com-
plex (MAC) and cell lysis. To determine which cells are
targeted for MAC formation, we used selective depletion
of proteins along the classical and common pathways
to prevent cell death and localize the deposition of





















































































Fig. 4 Kinetics of neuron, OL, and OPC loss in the presence of NMO rAb #53-mediated astrocyte injury. a Fluorescence (left) and phase contrast
IncuCyte (right) images of neuroglial mixed culture treated with rAb #53 plus 5% HC in the presence of DRAQ7 (PLP-eGFP oligodendrocytes [green]
and DRAQ7 dead cells [red]). Arrows: neurons. Arrow heads: astrocytes. Circled area: focal region of astrocyte depletion. b, c, d, and e Quantitation of
the percentage of DRAQ7+ AST (b), neuron (c), OL (d), and OPC (e) in the mixed cultures. Cells were identified as described in the Methods.
Statistical analyses were performed by multiple unpaired Student’s t test. **p < 0.01, n > 3. Scale bars 50 μm
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activated complement components. Using C5-depleted
HC, we arrested complement activation following C3
proteolytic cleavage resulting in C3d deposition on
complement-targeted cells (Fig. 9a). In neuronal monocul-
tures treated with C5-depleted HC, C3d was detected on
the cell surface. When neuronal monocultures were
treated with C4-depleted human complement (Fig. 9b),
there was no C3d deposition, indicating that activation of
the classical pathway was essential for neuronal injury
with HC alone. In neuroglial mixed cultures treated with
C5-depleted HC, C3d was detected on the surface of neu-
rons and OLs (arrows and arrow heads, respectively), but
not OPCs or surrounding astrocytes (Fig. 9c). Since HC-
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Fig. 5 HC causes mild neuronal and mature oligodendroglial cell loss in mouse organotypic cerebellar slice culture. Immunostaining and quantitation
of neuron and glia cell death in the slices treated with medium only (CTRL) or 10% HC for 48 h. a 25× (left panels) and 63× (right panels) objective
images of slices stained with AST marker GFAP. b, c Calbindin-positive Purkinje neurons show increased PI staining in the presence of HC. d, e PLP-
eGFP-positive OLs are mildly reduced in number following HC treatment for 48 h. 25× (upper) and 63× (lower) objective images of PLP-eGFP in slices
treated for 48 h (d). eGFP+ cell bodies were quantified at 8, 12, 24, and 48 h in multiple 20× fields (e). f, g Slices were treated for 48 h and co-stained
with Olig2 and NG2. Arrows mark Olig2+NG2+ OPCs. OPCs were counted at 24 or 48 h following HC administration. Statistical analyses were performed
by multiple unpaired Student’s t test. *p < 0.05, **p < 0.01, n≥ 3. Scale bars 50 μm
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astrocytes (Additional file 1: Figure S5), the resistance of
OPCs and astrocytes to CDC in mixed culture was either
due to the local expression of complement inhibitors or
the inability of surface-bound human IgGs to reach a suf-
ficient threshold to activate the complement cascade.
When mixed cultures were treated with NMO rAb #53
and C5-depleted HC, C3d deposits were found on the sur-
face of neurons (arrows), OLs (arrow heads), and sur-
rounding astrocytes (stars), but not on OPCs (Fig. 9c). In
organotypic cerebellar slices treated with C5-depleted or
complete HC, deposits of C3d and MAC were detected
along fibers containing neuro-filaments (Fig. 9d, arrows)
and surrounding oligodendrocyte cell bodies (Fig. 9d, ar-
rowheads). No detectable C3d or MAC deposits were
noted in slices exposed to medium alone (data not
shown). These results demonstrate that complement in
human serum is activated by human anti-murine cross-
reactive antibodies in primary cell monocultures, mixed
cultures, and cerebellar slice cultures.
Discussion
These studies demonstrated that activated human comple-
ment HC is injurious to mouse neurons and OLs in a var-
iety of culture conditions. We found that complement
activation is necessary for cell injury in primary cell and
slice cultures and occurs through the binding and activation
of the classical pathway by anti-murine immunoglobulin in
human sera. The susceptibility of neurons and glia to HC
in the culture system lessens as the CNS cells coalesce into
more complex networks. It may be that the different cul-
ture conditions (i.e., mono- or mixed cell cultures or tis-
sues) alter the expression profiles of individual cell types
resulting in loss of antigen expression, masking of target
epitopes, and/or acquisition of complement inhibition.
Each of these mechanisms may play a role in cell injury in
models of NMO lesions and need to be examined relative
to pathology in human tissue.
In primary cell monocultures, the addition of human
serum alone is sufficient to cause rapid and substantial
oligodendrocyte and neuronal cell death. In the neuro-
glial mixed cultures, the effects of activated complement
are likely reduced through protective oligodendroglial
and neuronal interactions with astrocytes. As a conse-
quence, astrocyte injury and loss driven by AQP4-specific
rAb and complement-mediated cytotoxicity rapidly in-
crease the level of neuronal and oligodendroglial damage.
Interestingly, OPCs in the neuroglial cultures are resistant
to complement attack following astrocyte damage. In
cerebellar tissue slices, cell-cell interactions are more
complex, and complement-mediated cell death of neurons
and OLs are further reduced. While astrocyte destruction
similarly increases oligodendroglial and neuronal cell
death, the susceptibility of these populations to comple-
ment cytotoxicity independent of astrocyte loss is much
less than that observed in cell cultures. OPCs are the not-
able exception, becoming sensitized in the presence of
astrocyte damage in organotypic slice culture (Table 1).
Our results suggest that the increasing complexity of the
neuroglia environment, particularly in slice cultures, pro-
tects neurons and oligodendrocytes from complement-
induced cytotoxicity, and astrocytes play a central role in
modulating complement injury. In the CNS of NMO
patients, additional factors other than CDC, such as exci-
totoxicity, inflammatory cytokines, antibody-dependent
cell-mediated cytotoxicity, anaphylaxotoxins, and dis-
rupted astrocyte physiology may play critical roles in
lesion formation (reviewed in [28]). Whether exposure of
tissue epitopes allows CDC to contribute to oligodendro-
cyte and neuronal injury in human NMO lesions remains
to be determined. Conversely, the use of complement
from multiple species will be necessary to validate the
relevance of oligodendroglial and neuronal damage ob-
served across in vitro, ex vivo, and in vivo NMO models.
Astrocytes are a major producer of complement in the
healthy and diseased CNS [29]. While astrocytes are not
sensitive to HC alone, astrocyte destruction occurs readily
through the production of terminal complement complexes
(MAC complex) with AQP4-specific antibodies. Indeed,
the current and previous studies demonstrate that inactiva-
tion of the classical or alternative pathway affects AQP4-
IgG mediated astrocyte cytotoxicity [16, 30]. Antibodies
a b
c d
Fig. 6 NMO rAb #53 and HC cause rapid astrocyte network destruction
in mouse brain slices. Images of slices treated with rAbs #53 and isotope
control rAb with or without 10% HC for 8 or 48 h and stained with GFAP.
a rAb #53 alone, 48 h. b rAb Iso with HC, 48 h. c rAb #53 with HC 8 h. d
rAb #53 with HC, 48 h. Iso: negative isotype control rAb. Scale bar 50 μm
Liu et al. Journal of Neuroinflammation  (2016) 13:301 Page 10 of 16
against factor B [31], a key regulator of alternative pathway,
or HC depleted of factor B, decrease astrocyte damage [16].
Neurons in monoculture were very sensitive to acti-
vated complement, in agreement with the previous
observations that neurons, unlike most peripheral cell
types, express complement receptors and regulators, but
do not express the most known complement inhibitors
[32, 33]. Neuronal damage in our in vitro and ex vivo
models occurred as the direct result of activated comple-
ment. This may, in part, explain why persistent neurologic
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Fig. 7 Increased neuron and OL death following astrocyte damage in brain slices. Immunostaining and quantification of neuron and oligodendrocyte
cell death in the slices treated with rAb NMO#53 or isotype control rAb with or without 10% HC for 48 h. PI-stained cells double stained with Purkinje
neuron marker Calbindin (a). Quantification of PI-labeled cells co-localized with Calbindin, as a percent of the total Calbindin+ cells (b). 25×
(upper panel) and 63× (lower panel) objective images of PLP-eGFP in slices (c). Quantification of eGFP+ OLs in slices at 8, 12, 24, and 48 h after
treatment (d). Cerebellar slices treated for 24 h with rAb #53 and HC were co-stained with Olig2 and NG2 to identify OPCs (e). Arrows mark
OPCs. f OPCs were counted in slices treated for 24 and 48 h. Iso: negative isotope control rAb. Statistical analyses were performed by multiple
unpaired Student’s t test for single comparison (f) or by two-way ANOVA for grouped comparisons (d). *p < 0.05, **p < 0.01, ***p < 0.001, ns
not significant, n ≥ 3. Scale bars 50 μm
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disability is strongly linked with acute relapses, as acti-
vated complement is prominent feature of acute NMO
lesions [1, 34, 35].
Consistent with previous reports [36], our results dem-
onstrated that oligodendrocytes were vulnerable to acti-
vated complement. Both in cell culture and brain slices,
OLs (O4+) were susceptible to the addition of HC inde-
pendent of the presence of astrocytes. Oligodendrocytes,
unlike astrocytes, lack the complement regulatory protein
CD59, which inhibits the final formation of membrane
attack complex [37–39]. Complement resistance in rat
oligodendrocytes can be restored by the incorporation of
purified rat CD59 into the cell membrane. Furthermore,
neutralization of rat CD59 on complement-resistant astro-
cytes rendered them susceptible to CDC [37]. When stud-
ied in mixed cultures or slice cultures with astrocytes and
neurons, OL susceptibility to complement was partially de-
creased (Table 1). One explanation is that the presence of
astrocytes or neurons may reduce the amount of the acti-
vated complement available for OL binding, mask OL
membrane epitopes, or alter OL membrane epitope expres-
sion. Alternatively, astrocytes or neurons may secrete, ex-
change, or modulate complement regulatory protein
expression on the oligodendrocyte surface. It has been
reported that in a mixed culture system of rat oligodendro-
cytes and dorsal root ganglion neurons, OLs are remarkably
Fig. 8 Anti-tissue antibodies and complement proteins in the human serum were required in the cytotoxicity to neurons, OPCs and OLs. a IgG-
depleted human serum by protein A/G agarose (A/GHC) were used in mixed culture and assayed for neuronal death by IncuCyte. Unlike HC, A/
GHC did not cause significant neuronal death. b With addition of NMO rAb #53, A/GHC caused astrocyte death at a reduced level compared with
#53+HC. c, d Serum protein or heat-inactivated human serum (c) or human serum with depletion of complement components were used in neuron
monoculture cytotoxicity assay (d). e, f Human serum (HC), or serum depleted of IgG by A/G agarose (A/GHC) or complement C1q (HC-C1q), were
used in OPC (e) or OL (f) monoculture cytotoxicity assays. LDH release was measured in the clarified cell-free supernatant collected from cultures
treated as indicated for 4 h. HC-protein: protein fractions of human serum retained from 3KD centrifugal filters, HC-HI: heat-inactivated human
serum, HC-C1q: C1q-depleted human serum, HC-C3: C3-depleted human serum, and HC-C9: C9-depleted human serum
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Fig. 9 (See legend on next page.)
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less sensitive to complement. Incubation of OLs with
neuron-conditioned medium afforded a similar protection
against complement-mediated lysis [40].
Our results demonstrate that OPCs remain resistant
to activated complement independent of the astrocyte
damage in mixed cultures. Unexpectedly, in organotypic
cerebellar slice cultures, astrocyte destruction enhanced
OPC loss. Although the neuroglia mixed cultures are
prepared from the cortex and the organotypic slices
from cerebellum, the differential sensitivity of OPCs to
astrocyte damage does not appear to result from distinc-
tions between cortical and cerebellar glia. In cell cultures
prepared from cerebellum, there are no significant differ-
ences in astrocyte death or OPC survival in the presence
of NMO rAb #53 and HC (unpublished data). Thus, it
appears that astrocyte damage in the complex neuroglia
network of cerebellar slices sensitizes OPCs to injury. In
addition, activated microglia, inflammatory mediators,
and excitotoxic molecules may combine to produce a
toxic milieu for OPCs in brain slices. Alternatively, the
state of differentiation of OPCs in that environment may
result in novel susceptibility to neuroinflammatory injury.
Following astrocyte damage, loss of oligodendrocytes,
both mature cells and progenitors, is observed earlier
than neuronal death in cerebellar slices. This is consist-
ent with reports that the loss of OLs and OPCs are early
pathologic features after astrocyte depletion in human
and experimental NMO lesions [41]. Vulnerability of oli-
godendrocytes is found in many neurological conditions.
In patients with relapsing-remitting multiple sclerosis
(RRMS), oligodendrocytes in affected tissue show apop-
totic features and myelin sheaths stain with activated
complement [42]. In a rat model of hypoxia-ischemic in-
jury and in a mouse model of amyotrophic lateral scler-
osis (ALS), extensive degeneration of differentiated
oligodendrocytes (O4+) is found before the loss of OPCs
[43, 44]. Although new oligodendrocytes are formed
from NG2+ OPCs in the spinal cord of ALS mice, they
fail to mature [44]. These observations in combination
with our results suggest a selective vulnerability of ma-
ture oligodendrocytes to multiple forms of injury. With
extreme conditions, such as massive astrocyte destruc-
tion in NMO, OPCs may also be affected.
Taken together, our findings demonstrate that in
mouse monoculture, activated human complement is
targeted to neurons, OLs and OPCs through the
action of anti-murine immunoglobulins. In mixed cul-
tures, surrounding astrocytes ameliorate CDC; tar-
geted destruction of astrocytes with AQP4-specific
recombinant monoclonal antibodies restores neuronal
and oligodendroglia susceptibility to HC. Increasing
complexity of neuroglial networks in murine cerebel-
lar slices further reduces the effects of activated hu-
man complement alone and alters the secondary
effects of astrocyte injury on OPC survival. Experi-
mental models of NMO require complement activa-
tion to initiate CNS lesions. Initial models involved
administration of AQP4-IgG to rats with pre-existing
neuroinflammation produced by experimental auto-
immune encephalomyelitis [12, 14, 45]. Although
some pathology resulted from the influx of myelin-
reactive T cells, lesions demonstrated hallmark fea-
tures of NMO pathology including perivascular astro-
cyte destruction and complement deposition.
Subsequent passive-transfer models of NMO in mice
required intracranial injection of NMO-IgG and hu-
man complement to recapitulate key pathological
findings in human lesions [30, 46, 47]. The use of hu-
man complement was required due to the presence of
inhibitors in mouse complement preparations [18,
19]. The current studies indicate that one should use
caution in interpreting the cause of secondary injury
to CNS cells following AQP4-IgG mediated CDC
when using human serum in murine models.
Conclusions
Our study demonstrates that mouse neurons, OLs, and
OPCs display variable sensitivity to activated HC based
on culture conditions and tissue complexity. In cell and
slice cultures, the protection of neurons, OLs, and OPCs
against HC is eliminated by targeted astrocyte destruc-
tion. Because of the targeted activation of HC on mouse
(See figure on previous page.)
Fig. 9 HC toxicity to mouse CNS cells requires activation of the classical complement cascade. a Simplified diagram of the complement cascade
depicting both the classical and alternative pathways. Red lines indicate the location of blocks in the complement pathway resulting from either
C4 or C5 depletion. b C3d staining in pure neuronal monocultures. Cultures were treated with medium only (CTRL), 5% C4-depeleted, or C5-depleted
human complement (C4depHC or C5depHC) for 30 min followed by live staining with anti-C3d antibody and DAPI. c C3d staining in neuroglial mixed
cultures. Mixed cultures prepared from PLP-eGFP mouse pups were incubated with medium only (CTRL), 5% C4depHC, or 5% C5depHC in the
presence/absence of NMO rAb #53 for 30 min followed by live staining of C3d. Cells were then fixed and stained with neuronal marker
β-Tubulin and DAPI. Note: In mixed cultures treated with C5depHC alone, C3d was present on the surface of neurons (N, arrows) and differentiated
OLs (OL, arrow heads), which were sensitive to HC. In cell cultures treated with NMO rAb #53 plus C5depHC, C3d was detected on the surface of
neurons (arrows), OLs (arrow heads), and surrounding astrocytes (stars). No C3d staining was observed on OPCs in mixed cultures. d C3d
and MAC staining in slice culture. PLP-eGFP slices were treated with 10% C5depHC or human complement (HC) for 48 h and stained with
C3d and MAC, respectively. Neurofilament was visualized with NF-H staining. Deposits of C3d or MAC were detected along the NF-H+
processes (arrows) and surrounding the oligodendrocyte cell bodies (arrow heads). Scale bars 50 μm
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CNS cells, caution is needed in interpreting the relation-
ship between damage in experimental mouse models of
NMO and human lesions.
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nuclei dye DRAQ7). (MOVIE 4218.88 kb)
Additional file 4: Movie 3. Co-culture with HC. IncuCyte live cell imaging
in neuro-glial co-cultures prepared from PLP-eGFP mouse pups and treated
with 5% HC. Cell cultures were scanned for 66 hr. Images were captured at
15 min intervals with high definition phase contrast and green (to detect
eGFP + OPC and differentiated OL) and red fluorescence (to detect the
dead cell nuclei dye DRAQ7). (MOVIE 18534.4 kb)
Additional file 5: Movie 4. Co-culture with NMO53 + HC. IncuCyte live
cell imaging in neuro-glial co-cultures prepared from PLP-eGFP mouse pups
and treated with NMO rab#53 plus 5% HC. Cell cultures were scanned for
66 hr. Images were captured at 15 min intervals with high definition phase
contrast and green (to detect eGFP + OPC and differentiated OL) and red
fluorescence (to detect the dead cell nuclei dye DRAQ7). Around the area
marked with "A": dead astrocytes floated into the culture supernatant,
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areas. (MOVIE 34099.2 kb)
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